Examination of the effect of food containing WB21 on oral Candida species (Randomized, placebo-controlled, double-blind, parallel-group comparative study)

Examination of the effect of food containing Lactobacillus salivarius WB21 on oral Candida species (Randomized, placebo-controlled, double-blind, parallel-group comparative study) - Effect of Lactobacillus salivarius WB21-containing tablets on oral Candida (RCT)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000058770

Enrollment

Registered

2025-10-01

Start date

2025-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

oral candidiasis

Interventions

Study participants will be asked to take &quot

Avambees Oral Tablets&quot

(Wakamoto Pharmaceutical Co., Ltd.), a food containing Lactobacillus salivarius WB21, three times a day for two weeks. Study participants will take placebo tablets (Wakamoto Pharmaceutical Co., Ltd.)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Residents of a certain nursing home in Fukuoka City who has been found to have Candida in his or her oral cavity

Exclusion criteria

Exclusion criteria: Those who are already using food containing WB21 / Those taking antibiotics / Those with a history of milk allergy or food allergy to food ingredients / Those who the researcher judges to be inappropriate as study participants

Design outcomes

Primary

Measure	Time frame
the number of Candida species in the mouth	—

Countries

Japan

Contacts

Public ContactNao Taniguchi

Fukuoka Dental College Department of Preventive and Public Health Dentistry

naojsz@fdcnet.ac.jp81-92-801-0616

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026